Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 HHS Cancels Moderna's $590M mRNA Avian Flu Vax Award | Contract Pharma

What are you searching for?

Sign in
Breaking News

HHS Cancels Moderna’s $590M mRNA Avian Flu Vax Award

HHS previously awarded $176 million for a mRNA-based vaccine against the H5N1 avian influenza.

Moderna, Inc. received notice that the U.S. Department of Health and Human Services (HHS) will terminate the award for the late-stage development and right to purchase influenza vaccines.

In January, Moderna was awarded $590 million by the Biden administration to advance the development of its bird flu vaccine, and expansion of clinical studies for up to five additional subtypes of influenza. The HHS previously awarded $176 million to complete the late-stage development and testing of a mRNA-based vaccine against the H5N1 avian influenza.

The Phase 1/2 study (NCT05972174) is currently evaluating the safety and immunogenicity of a two-dose regimen of its investigational influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. 

Moderna will explore alternatives for late-stage development and manufacturing of the H5 program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics